We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
Read MoreHide Full Article
Key Takeaways
KT-621 drove deep STAT6 degradation and strong biomarker reductions in KYMR's phase Ib BroADen study.
KT-621 showed notable EASI and pruritus improvements, plus benefits in asthma and allergic rhinitis patients.
KT-621 was well-tolerated, and KYMR has advanced it into a phase IIb study with data expected in 2027.
Shares of Kymera Therapeutics (KYMR - Free Report) were up 41.6% yesterday after the company announced positive data from the phase Ib BroADen study, which evaluated its lead pipeline candidate KT-621 for treating atopic dermatitis (AD), also known as eczema.
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of type 2 inflammation.
Year to date, shares of Kymera have rallied 134.4% compared with the industry’s rise of 19.3%.
Image Source: Zacks Investment Research
More on the Data from KYMR’s BroADen Study
The open-label, single-arm phase Ib BroADen study evaluated KT-621 across two doses (100 mg and 200 mg) in patients with moderate-to-severe AD.
Data from the study showed that treatment with KT-621 led to deep STAT6 degradation in both the 100 mg and 200 mg doses, with median reductions of 94% in the skin and 98% in the blood, showing that the candidate’s effects in healthy volunteers translated well to AD patients.
Treatment with KT-621 also led to strong reductions in disease-relevant type 2 biomarkers in blood, including Thymus and Activation-Regulated Chemokine (TARC) – median reduction of 74% in patients with baseline TARC levels comparable to Sanofi’s (SNY - Free Report) Dupixent (dupilumab) studies on AD, Eotaxin-3, IL-31, IgE, and in core type 2 inflammation and AD disease-relevant gene sets in skin lesions.
KT-621 demonstrated strong clinical activity across all measured endpoints in the phase Ib BroADen study, including a mean 63% reduction in Eczema Area and Severity Index (EASI) and a mean 40% reduction in peak pruritus Numerical Rating Scale (NRS).
Patients with asthma who received KT-621 experienced a median 56% reduction in FeNO along with improvements in asthma control. Also, patients with allergic rhinitis who received KT-621 experienced significant symptom relief and better quality of life.
Treatment with KT-621 was generally safe and well-tolerated, with no serious adverse side effects observed.
The positive phase Ib BroADen results highlight KT-621’s potential as a first-in-class, once-daily oral therapy for type 2 inflammatory diseases. Its week-4 outcomes were comparable to—and in some cases exceeded—published data for SNY’s blockbuster drug, Dupixent, which is approved for several types of inflammatory diseases, including moderate-to-severe AD.
KYMR’s Other Development Activities
Kymera recently initiated dosing in the phase IIb study, BROADEN2, evaluating KT-621 in patients with moderate-to-severe AD. It expects to report data from the BROADEN2 trial by mid-2027.
Meanwhile, Kymera is on track to initiate a phase IIb study, BREADTH, in moderate-to-severe asthma patients in the first quarter of 2026.
Conducting parallel phase IIb studies in AD and asthma is expected to accelerate KT-621’s development and determine the appropriate dosing strategy for subsequent parallel phase III registrational programs spanning several type 2 dermatology, gastroenterology and respiratory conditions.
In the absence of a marketed product, the successful development of its pipeline candidates remains the key focus area for Kymera.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have increased from $7.28 to $7.54. EPS estimates for 2026 have moved up from $7.78 to $8.15 during the same period. ANIP stock has surged 47.2% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from 65 cents to 23 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $2.10 to $1.42. Year to date, shares of CSTL have rallied 43%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, the average surprise being 66.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
Key Takeaways
Shares of Kymera Therapeutics (KYMR - Free Report) were up 41.6% yesterday after the company announced positive data from the phase Ib BroADen study, which evaluated its lead pipeline candidate KT-621 for treating atopic dermatitis (AD), also known as eczema.
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of type 2 inflammation.
Year to date, shares of Kymera have rallied 134.4% compared with the industry’s rise of 19.3%.
Image Source: Zacks Investment Research
More on the Data from KYMR’s BroADen Study
The open-label, single-arm phase Ib BroADen study evaluated KT-621 across two doses (100 mg and 200 mg) in patients with moderate-to-severe AD.
Data from the study showed that treatment with KT-621 led to deep STAT6 degradation in both the 100 mg and 200 mg doses, with median reductions of 94% in the skin and 98% in the blood, showing that the candidate’s effects in healthy volunteers translated well to AD patients.
Treatment with KT-621 also led to strong reductions in disease-relevant type 2 biomarkers in blood, including Thymus and Activation-Regulated Chemokine (TARC) – median reduction of 74% in patients with baseline TARC levels comparable to Sanofi’s (SNY - Free Report) Dupixent (dupilumab) studies on AD, Eotaxin-3, IL-31, IgE, and in core type 2 inflammation and AD disease-relevant gene sets in skin lesions.
KT-621 demonstrated strong clinical activity across all measured endpoints in the phase Ib BroADen study, including a mean 63% reduction in Eczema Area and Severity Index (EASI) and a mean 40% reduction in peak pruritus Numerical Rating Scale (NRS).
Patients with asthma who received KT-621 experienced a median 56% reduction in FeNO along with improvements in asthma control. Also, patients with allergic rhinitis who received KT-621 experienced significant symptom relief and better quality of life.
Treatment with KT-621 was generally safe and well-tolerated, with no serious adverse side effects observed.
The positive phase Ib BroADen results highlight KT-621’s potential as a first-in-class, once-daily oral therapy for type 2 inflammatory diseases. Its week-4 outcomes were comparable to—and in some cases exceeded—published data for SNY’s blockbuster drug, Dupixent, which is approved for several types of inflammatory diseases, including moderate-to-severe AD.
KYMR’s Other Development Activities
Kymera recently initiated dosing in the phase IIb study, BROADEN2, evaluating KT-621 in patients with moderate-to-severe AD. It expects to report data from the BROADEN2 trial by mid-2027.
Meanwhile, Kymera is on track to initiate a phase IIb study, BREADTH, in moderate-to-severe asthma patients in the first quarter of 2026.
Conducting parallel phase IIb studies in AD and asthma is expected to accelerate KT-621’s development and determine the appropriate dosing strategy for subsequent parallel phase III registrational programs spanning several type 2 dermatology, gastroenterology and respiratory conditions.
In the absence of a marketed product, the successful development of its pipeline candidates remains the key focus area for Kymera.
KYMR’s Zacks Rank & Stocks to Consider
Kymera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) and Castle Biosciences (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have increased from $7.28 to $7.54. EPS estimates for 2026 have moved up from $7.78 to $8.15 during the same period. ANIP stock has surged 47.2% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 21.24%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from 65 cents to 23 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from $2.10 to $1.42. Year to date, shares of CSTL have rallied 43%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, the average surprise being 66.11%.